peptide
Adipotide (FTPP)
anecdotalResearch Use OnlyInjection
DISCONTINUED. Experimental peptide that cuts blood supply to fat cells. Terminated due to unacceptable kidney toxicity in primates. No human trials conducted.
Key facts
- Classification
- Peptide — DISCONTINUED: Experimental peptide that cuts blood supply to fat cells. Terminated due to kidney toxicity.
- Primary benefits
- Fat Loss (4/10)
- Administration
- Injection
- Doses studied
- Primate study (Barnhart et al. 2011, PMID 22072637, Science Translational Medicine 3:108ra112): doses of 0.10, 0.25, 0.43, and 0.75 mg/kg subcutaneous daily × 28 days tested; experimentally optimal dose was 0.43 mg/kg. Renal effects were mild, dose-dependent, and reversible (tubular degeneration/regeneration and single-cell necrosis at 0.75 mg/kg; serum creatinine returned toward baseline during 28-day recovery). Phase 1 human trial (NCT01262664, Arrowhead/MD Anderson) administered adipotide subcutaneous daily × 28 days; starting dose was 0.03 mg/kg (sponsor announcement); trial terminated January 2019, no human efficacy data published. The 0.01 mg/kg research-protocol dose and 2-week cycle limit cited in secondary sources have no PubMed-indexed primary basis; both primate and human primary studies used 28-day cycles. No human clinical dose established. Monitor renal function. Use at your own risk.
- Evidence strength
- Anecdotal — 8 peer-reviewed studies
- Legal status
- Research Use Only · not prescribable in US
Quick stats
- Type
- Peptide
- Administration
- Injection
- Studies referenced
- 8
- Stacks with
- 0 peptides
- Regulatory
- Research Use Only
Goal coverage · Adipotide (FTPP)
🔥 Fat Loss4/10
Medical oversight requiredNot safe during pregnancy· 5 contraindications